Prucalopride: A review of its use in the management of chronic constipation

Drugs

Volumn 73, Issue 17, 2013, Pages 1935-1950

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE PLUS MACROGOL 3350 PLUS POTASSIUM CHLORIDE PLUS SODIUM CHLORIDE; LAXATIVE; PLACEBO; PRUCALOPRIDE; RESOTRAN; UNCLASSIFIED DRUG;

ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CHRONIC CONSTIPATION; CONSTIPATION; DEFECATION HABIT; DIARRHEA; DRUG ABSORPTION; DRUG CHOICE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; FOLLOW UP; GASTROINTESTINAL MOTILITY; HEART PALPITATION; HUMAN; INTESTINE FUNCTION; INTESTINE MOTILITY; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PATIENT SATISFACTION; PHARYNGITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME; URINARY TRACT INFECTION;

BENZOFURANS; CHRONIC DISEASE; CONSTIPATION; HUMANS; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN 5-HT4 RECEPTOR AGONISTS; TIME FACTORS;

EID: 84892622812     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0140-1     Document Type: Article

References (71)

1. Tack J, Müller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation: a European perspective. Neu-rogastroenterol Motil. 2011;23(8):697-710.
2. 4) receptor agonist, for the treatment of chronic constipation. Clin Exp Gastroentrol. 2010;3:49-56.
3. Quigley EMM. Prucalopride: safety, efficacy and potential applications. Ther Adv Gastroenterol. 2012;5(1):23-30.
4. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91.
5. Liu LWC. Chronic constipation: current treatment options. Can J Gastroenterol. 2011;25 Suppl B:22B-8B.
6. European Medicines Agency. Resolor (prucalopride) film-coated tablets: EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR- Product-Information/human/001012/WC500053998.pdf (Accessed 8 Oct 2013).
7. Emmanuel AV, Kamm MA, Roy AJ, et al. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut. 1998;42(4):511-6.
8. Poen AC, Felt-Bersma RJF, Van Dongen PAM, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther. 1999;13(11):1493-7.
9. 4 agonist, prucalopride, in healthy humans. Gut. 1999;44(5):682-6.
10. 4 receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther. 2002;16(3):603-12.
11. Kessing BF, Smout AJ, Bennink RJ, et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects [abstract no. 745]. Gastroenterology. 2013;144(5 Suppl 1):S134.
12. Boyce MJ, Kerstens R, Beyens G, et al. Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trials [abstract no. T1265]. Gastroenterology. 2009;136(5 Suppl 1):A535.
13. Mendzelevski B, Ausma J, Chanter DO, et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo-and positive-controlled thorough QT study. Br J Clin Pharmacol. 2012;73(2):203-9.
14. Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief: results of a double-blind, placebo-controlled clinical trial. Digestion. 2003;67(1-2):82-9.
15. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120(2):354-60.
16. Sloots CEJ, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 2002;16(4):759-67.
17. Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 2002;16(7):1347-56.
18. Emmanuel AV, Kerstens R, Vandeplassche LM. Prucalopride improves bowel function and colonic transit time in patients with constipation [abstract no. Mo1326]. Gastroenterology. 2011;140 (5 Suppl 1):S612.
19. Briejer MR, Bosmans J-P, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001;423(1):71-83.
20. 4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20(2):99-112.
21. Mader R, Kocher T, Haier J, et al. Investigation of serotonin type 4 receptor expression in human and non-human primate gastrointestinal samples. Eur J Gastroenterol Hepatol. 2006;18(9): 945-50.
22. 4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol. 2000;131(5):927-32.
23. 4 receptors in the human isolated large intestinal circular muscle. Br J Pharmacol. 2000;129(8): 1601-8.
24. 4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol. 1999;127(6):1431-7.
25. Briejer MR, Prins NH, Schuurkes JAJ. Effects of the enteroki-netic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil. 2001;13(5):465-72.
26. Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K channel and the common T897 polymorph. Eur J Pharmacol. 2007;554(2-3): 98-105.
27. Potet F, Bouyssou T, Escande D, et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K channel. J Pharmacol Exp Ther. 2001;299(3): 1007-12.
28. European Medicines Agency. Resolor (prucalopride): EU public assessment report. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/001 012/WC500053997.pdf (Accessed 8 Oct 2013).
29. Pau D, Workman AJ, Kane KA, et al. Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with b-adrenoceptor antagonists. J Pharmacol Exp Ther. 2005;313(1):146-53.
30. 4 splice variants. Naunyn Schmiedebergs Arch Pharmacol. 2005;371(6):473-9.
31. 4 receptor-mediated response in pig atrium but not in stomach. Br J Pharmacol. 2009;156(2):362-76.
32. 4 receptor-induced responses: fading of the response and influence of development. Br J Pharmacol. 2006;147(2):140-57.
33. Van de Velde VJ, Ausma J, Vandeplassche L. I.V. kinetics and absolute oral bioavailability of prucalopride [abstract no. S1331]. Gastroenterology. 2010;138(5 Suppl 1):S230.
34. Van de Velde VJ, Ausma J, Vandeplassche L. Food does not affect the oral bioavailability of prucalopride [abstract no. T1270]. Gastroenterology. 2009;136(5 Suppl 1):A536.
35. Van de Velde VJ, Ausma J, Vandeplassche L. Comparative pharmacokinetics of prucalopride in healthy young and elderly subjects [abstract no. S1330]. Gastroenterology. 2010;138(5 Suppl 1):S230.
36. Chen X, Jiang J, Liu T, et al. Pharmacokinetics of single and repeated oral doses of prucalopride in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2012;50(11):797-804.
37. TM (prucalopride) tablets: Australian prescribing information. 2011. https://www.ebs.tga.gov.au (Accessed 8 Oct 2013).
38. TM (prucalopride) tablets: Canadian prescribing information. 2012. http://www.hc-sc.gc.ca (Accessed 8 Oct 2013).
39. Winter HS, Di Lorenzo C, Benninga MA, et al. Oral prucalopride in children with functional constipation. J Pediatr Gastroenterol Nutr. 2013;57(2):197-203.
40. Smith WB, Mannaert E, Verhaeghe T, et al. Effect of renal impairment on the pharmacokinetics of prucalopride: a single-dose open-label phase I study. Drug Des Dev Ther. 2012;6:407-15.
41. Van de Velde V, Vandeplassche L, Hoppenbrouwers M, et al. Effect of prucalopride on the pharmacokinetics of oral contraceptives in healthy women. Drugs R D. 2013;13(1):43-51.
42. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344- 54.
43. Quigley EMM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29(3):315-28.
44. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58(3):357-65.
45. Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogas-troenterol Motil. 2012;24(11):999-e541.
46. Müller-Lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil. 2010;22(9): 991-8, e255.
47. Gatta L, Kerstens R, Scarpignato C. How effective is prucalo-pride for the treatment of chronic constipation? A systematic review and meta-analysis [abstract no. Su2069]. Gastroenterol-ogy. 2013;144(5 Suppl 1):S547-8.
48. Cheng E. Efficacy of prucalopride in the treatment of chronic constipation: a systematic review and meta-analysis of randomized controlled trials [abstract]. Clin Gastroenterol Hepatol. 2012;10(3):329-30.
49. Tack J, Quigley E, Camilleri M, et al. Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. United Eur Gastroen-terol J. 2013;1:48-59.
50. Tack J, Stanghellini V, Dubois D, et al. Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil. 2013;. doi:10.1111/nmo.12217.
51. Ke MY, Zou DW, Yuan YZ, et al. Treatment with prucalopride for chronic constipation improves the symptoms and quality of life of patients in China [abstract no. PGI16]. Value Health. 2012;15(7):A637-8 plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research 5th Asia-Pacific Conference; 2-4 Sep 2012; Taipei.
52. Stanghellini V, Vandeplassche L, Kerstens R. Best response distribution of 12-week treatment with prucalopride (Resolor) in patients with chronic constipation: combined results of three randomised, double-blind, placebo-controlled phase III trials [abstract no. PWE-075]. Gut. 2011;60 Suppl 1:A159-60.
53. Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation-follow-up of patients from the pivotal studies. Aliment Pharmacol Ther. 2010;32(9):1113-23.
54. Cinca R, Chera D, Gruss H-J, et al. Randomised clinical trial: macrogol/PEG 3350 ? electrolytes versus prucalopride in the treatment of chronic constipation: a comparison in a controlled environment. Aliment Pharmacol Ther. 2013;37(9):876-86.
55. Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009;21(12): 1256-63, e117.
56. Movetis. Movetis receives authorisation to market Resolor in Switzerland [media release]; 2010. http://www.movetis.com (Accessed 8 Oct 2013).
57. Lacy BE, Levenick JM, Crowell M. Chronic constipation: new diagnostic and treatment approaches. Ther Adv Gastroenterol. 2012;5(4):233-47.
58. Lindberg G, Hamid SS, Malfertheiner P, et al. World Gastroenterology Organisation global guideline: constipation-a global perspective. J Clin Gastroenterol. 2011;45(6):483-7.
59. Bove A, Bellini M, Battaglia E, et al. Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment). World J Gastroenterol. 2012;18(36):4994-5013.
60. Portalatin M, Winstead N. Medical management of constipation. Clin Colon Rectal Surg. 2012;25(1):12-9.
61. Herring C. Prucalopride. Clin Pharmacist. 2011;3(2):55-7.
62. Shire Development LLC. Evaluation of prucalopride in male subjects with chronic constipation [ClinicalTrials.gov identifier NCT01147926]. US National Institutes of Health, ClinicalTri-als.gov; 2013. http://www.clinicaltrials.gov/ ct2/show/NCT0114 7926 (Accessed 8 Oct 2013).
63. Shire-Movetis NV. Study to investigate prucalopride vs. polyethylene glycol 3350 on colon activity [ClinicalTrials.gov identifier NCT01707667]. US National Institutes of Health, ClinicalTrials.gov; 2013. http://www. clinicaltrials.gov/ct2/show/NCT01707667 (Accessed 8 Oct 2013).
64. Stanghellini V, Vandeplassche LM, Kerstens R, et al. The relation between adverse events on day 1 and pharmacodynamic effects on day 1 of treatment with prucalopride [abstract no. Mo1336]. Gastroenterology. 2011;140(5 Suppl 1):S615.
65. 4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35(7): 745-67.
66. 4 receptor: what role for prucalopride? Clin Med Insights Gastroenterol. 2010;3:21-33.
67. Tack J, Corsetti M. Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. Expert Opin Drug Metab Toxicol. 2012;8 (10):1327-35.
68. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58(1):32-45.
69. Sloots CEJ, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55(10): 2912-21.
70. Movetis. Prucalopride effects on subjects with chronic non-cancer pain suffering from opioid induced constipation (OIC) [ClinicalTrials.gov identifier NCT01117051]. US National Institutes of Health, ClinicalTrials.gov; 2013. http://www.clinicaltrials.gov/ct2/show/results/NCT01117051 (Accessed 8 Oct 2013).
71. Emmanuel AV, Kamm MA, Roy AJ, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction-a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther. 2012;35(1):48-55.